Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
6.1 ^DKK	+3.39%		0.00%	-15.98%

Feb. 29	Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

TOMORROW IS THE LAST DAY OF THE SUBSCRIPTION PERIOD IN CESSATECH'S RIGHTS ISSUE

November 08, 2022 at 05:20 am EST

København, Denmark, November 8, 2022 - Cessatech A/S ("Cessatech" or the "Company") announces that the subscription period for the Company's rights issue of shares (the "Rights Issue" or the "Offering") ends tomorrow. The Rights Issue is also open for subscriptions to the public.

One (1) existing share in Cessatech held on the record date of October 25, 2022, entitles to one (1) Unit Right.
Four (4) Unit Rights entitles to subscription of one (1) Unit. One (1) Unit comprise of six (6) new shares and three (3) warrants of series TO2 free of charge.
The subscription price is DKK 12 per unit, corresponding to DKK 2 per share.
The Subscription period of the Rights Issue runs from October 27 up until November 9, 2022, both days included.
The Offering Memorandum, the application form and other information about the Offering is available on the Company's website, www.cessatech.com as well as on www.nordnet.se and www.nordnet.dk.

Advisors
Translution Capital acts as financial advisors to the Company in connection with the Offering. Nordic Issuing is the Company's issuing agent whereas Elmann Law Firm is the Company's legal advisor in connection with the Offering.

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development.

https://news.cision.com/cessatech/r/tomorrow-is-the-last-day-of-the-subscription-period-in-cessatech-s-rights-issue,c3663321

https://mb.cision.com/Main/19921/3663321/1655377.pdf

Latest news about Cessatech A/S

Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	23-10-25	CI
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	23-09-21	CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	23-09-12	MT
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation	23-09-12	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Cessatech A/S Secures DKK 5 Million Loan Facility Agreement to Support the US Launch of its Lead Program CT001	23-08-17	CI
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001	23-06-27	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-29	CI
Cessatech A/S Appoints Martin Olin as the Chairman of the Board	23-03-23	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-01	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Cessatech A/S Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18	CI
Cessatech to Raise $2 Million in Rights Offer	22-11-14	MT
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate	22-09-23	CI
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate	22-09-05	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval	22-06-30	CI
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate	22-05-16	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-19	CI
Cessatech A/S Announces Board Changes	22-03-17	CI
Cessatech Reports Successful Outcome of Bioavailability Trial 0204 with CT001	22-03-08	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-24	CI

Chart Cessatech A/S

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data